Urodynamix Technologies Ltd.
TSX VENTURE : URO

Urodynamix Technologies Ltd.

November 24, 2008 09:00 ET

Urodynamix Presents First Data on Use of NIRS and Transurethral Microwave Therapy at the 26th World Congress of Endourology Conference

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Nov. 24, 2008) - Urodynamix Technologies Ltd. (TSX VENTURE:URO) announced today that a multinational team will present an abstract highlighting the use of Urodynamix's near infrared spectroscopy (NIRS) technology for non-invasive measurement of blood flow changes during minimally invasive treatments for benign prostatic hyperplasia (BPH).

The abstract, entitled "Initial report of near infrared spectroscopy (NIRS) for non-invasive measurement of blood volume and flow changes to provide treatment feedback during prostate thermal therapies for BPH" will be presented by Prof. Limin Liao of the China Rehabilitation Research Center, David Robertson of Boston Scientific Corporation, and Dr. Luya Li of Urodynamix Technologies. The published abstract will be posted to Urodynamix's website and will also appear on the World Congress of Endourology website at www.chinamed.com.cn/wce2008. The presentation will take place at the 26th Annual Meeting of the World Congress of Endourology (WCE) at the Shanghai International Convention Center, November 30, 2008 in Shanghai, China.

A current limitation of transurethral microwave thermotherapy (TUMT) devices is that individual variations in prostate blood flow can limit the effectiveness of the procedure by removing the energy directed at the prostate during the treatment. Urodynamix is developing a non-invasive prostate blood volume flow monitor to help physicians determine when sufficient thermal energy has been delivered by TUMT and other minimally invasive therapies to destroy enlarged prostate tissue and BPH while improving the safety profile.

About the Study

Animal studies were conducted by Prof. Limin Liao at the Capital Medical University in Beijing from June 2007 to November 2008. The investigators collected NIRS readings simultaneously with the delivery of TUMT with the Prolieve™ Thermodilatation System manufactured by Boston Scientific Corp. The results showed that NIRS monitoring of the prostate and rectal wall for changes in blood volume-flow may provide the ability to non-invasively monitor the progress of tissue coagulation and necrosis during thermal therapies. This may allow physicians to optimize treatment despite variations in prostate blood flow of individuals.

About the World Congress of Endourology

The 26th World Congress of Endourology (WCE) conference is being organized by the Chinese Urological Association (CUA) in association with Chinese Medical Association, under the auspices of the Endourological Society.

About Urodynamix Technologies Ltd.

Urodynamix Technologies is a Canadian medical device company developing and commercializing non-invasive medical technology based on proprietary applications of near-infrared spectroscopy (NIRS). The Company is currently focused on products that aid in the diagnosis and treatment of urinary incontinence, lower urinary tract symptoms, prostate cancer, erectile dysfunction, benign prostatic hyperplasia, and traumatic increases in intra-abdominal pressure that cause abdominal compartment syndrome. Urodynamix's breakthrough medical technology has the potential to beneficially affect more than 200 million people worldwide.

Certain information contained in this press release may be forward-looking and is subject to unknown risks, which could cause actual results to differ materially from those set forth or implied herein. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Contact Information